New treatments for bacterial keratitis by Lai, JSM et al.
Title New treatments for bacterial keratitis
Author(s) Wong, RLM; Gangwani, RA; Yu, LWH; Lai, JSM
Citation Journal of Ophthalmology, 2012, v. 2012, article no. 831502
Issued Date 2012
URL http://hdl.handle.net/10722/191102
Rights Creative Commons: Attribution 3.0 Hong Kong License
Hindawi Publishing Corporation
Journal of Ophthalmology
Volume 2012, Article ID 831502, 7 pages
doi:10.1155/2012/831502
Review Article
New Treatments for Bacterial Keratitis
Raymond L. M. Wong,1 R. A. Gangwani,1 Lester W. H. Yu,2 and Jimmy S. M. Lai1
1 Eye Institute, The University of Hong Kong, Room 301, Level 3, Block B, 100 Cyberport Road, Cyberport 4, Hong Kong
2Department of Ophthalmology, Queen Mary Hospital, Hong Kong
Correspondence should be addressed to Jimmy S. M. Lai, laism@hku.hk
Received 31 May 2012; Revised 30 July 2012; Accepted 19 August 2012
Academic Editor: Rajesh Sinha
Copyright © 2012 Raymond L. M. Wong et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. To review the newer treatments for bacterial keratitis. Data Sources. PubMed literature search up to April 2012.
Study Selection. Key words used for literature search: “infectious keratitis”, “microbial keratitis”, “infective keratitis”, “new
treatments for infectious keratitis”, “fourth generation fluoroquinolones”, “moxifloxacin”, “gatifloxacin”, “collagen cross-linking”,
and “photodynamic therapy”. Data Extraction. Over 2400 articles were retrieved. Large scale studies or publications at more
recent dates were selected. Data Synthesis. Broad spectrum antibiotics have been the main stay of treatment for bacterial keratitis
but with the emergence of bacterial resistance; there is a need for newer antimicrobial agents and treatment methods. Fourth-
generation fluoroquinolones and corneal collagen cross-linking are amongst the new treatments. In vitro studies and prospective
clinical trials have shown that fourth-generation fluoroquinolones are better than the older generation fluoroquinolones and
are as potent as combined fortified antibiotics against common pathogens that cause bacterial keratitis. Collagen cross-linking
was shown to improve healing of infectious corneal ulcer in treatment-resistant cases or as an adjunct to antibiotics treatment.
Conclusion. Fourth-generation fluoroquinolones are good alternatives to standard treatment of bacterial keratitis using combined
fortified topical antibiotics. Collagen cross-linking may be considered in treatment-resistant infectious keratitis or as an adjunct to
antibiotics therapy.
1. Introduction
Infectious keratitis is a potentially blinding ocular condition
of cornea which can cause severe visual loss if not treated
at early stage. If the appropriate antimicrobial treatment is
delayed, only 50% of the eyes gain good visual recovery
[1]. It can be caused by bacteria, virus, fungus, protozoa,
and parasites. The common risk factors for infectious
keratitis include ocular trauma, contact lens wear, recent
ocular surgery, preexisting ocular surface disease, dry eyes,
lid deformity, corneal sensational impairment, chronic use
of topical steroids, and systemic immunosuppression [2–
5]. The common pathogens include Staphylococcus aureus,
coagulase-negative Staphylococcus, Pseudomonas aeruginosa,
Streptococcus pneumonia, and Serratia species. The majority
of community acquired cases of bacterial keratitis resolve
with empiric treatment and do not require culture [6].
Corneal scraping for culture and sensitivity is indicated for
corneal ulcers that are large in size, central in location,
extend from middle to deep stroma, associated with pain,
simultaneous presence of anterior chamber reaction or
hypopyon, poor vision, and presence of corneal abscess
or unresponsive to broad spectrum antibiotic therapy [6].
Recent studies have shown increasing evidence of resistance
of microbes to antimicrobial agents [7–9]. Microorganisms
develop resistance due to chromosomal mutation, expression
of latent chromosomal genes by induction or exchange of
genetic material via transformation [9, 10]. This can cause
continued progression of the disease process despite the use
of broad spectrum antibiotics. The purpose of this study
was to review the newer treatments available for treating the
infectious keratitis including those which are resistant to the
antimicrobial therapy.
2. Methods
A PubMed literature search was conducted up to April
2012 using the following key words: “infectious keratitis”,
“microbial keratitis”, “infective keratitis”, “new treatments for
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infectious keratitis”, “fourth generation fluoroquinolones”,
“moxifloxacin”, “gatifloxacin”, “collagen cross-linking”, and
“photodynamic therapy”. Articles reporting the efficacies of
using fourth-generation fluoroquinolones or photodynamic
therapy in the treatment of infectious keratitis were selected
and analyzed. During selection of the articles, prospective
studies had a higher ranking than the retrospective studies,
and clinical/in vivo studies had higher ranking than in vitro
studies.
3. Highlights of Literature Review
3.1. Infectious Keratitis. Corneal ulcer or infectious keratitis
is a serious condition of cornea that requires prompt
management. When a patient presents with the features
of infectious keratitis, clinical history and detailed clinical
examination guide to the category of high risk or low risk
characteristics [3]. Presence of history of ocular trauma,
contact lens use, preexisting ocular surface disease, history of
long term or injudicious use of topical steroids, large size of
ulcer, and central location of ulcer are considered to be high
risk characteristics. According to the American Academy of
Ophthalmology guidelines for bacterial keratitis, most of the
cases of community acquired infectious keratitis respond to
the empirical treatment with antibiotics. Corneal scraping is
indicated for corneal ulcers that are large in size, central in
location, extend frommiddle to deep stroma, associated with
pain, simultaneous presence of anterior chamber reaction
or hypopyon, poor vision, and presence of corneal abscess
or unresponsive to broad spectrum antibiotic therapy [6].
The culture-guided approach consists of taking a sample of
corneal tissue by corneal scraping or biopsy and performing
microbiological tests to determine the type of bacterial
organisms and their sensitivity to the particular group of
antibiotics. However, empirical antibiotics will usually be
started after microbiological specimens have been collected
if there is clinical suspicion of infection.
4. Treatment Options
4.1. Fluoroquinolones. Fluoroquinolones are synthetic broad
spectrum antibiotics. They inhibit DNA gyrase (topoiso-
merase II) and topoisomerase IV enzyme, which are key
enzymes involved in DNA replication and transcription
[11]. Inhibition of these enzymes will lead to bacterial
cell death [12]. Topoisomerase IV is the main target for
most Gram-positive bacteria. DNA gyrase on the other
hand is the main target for Gram-negative bacteria [12].
Nalidixic acid, the first generation fluoroquinolone, was used
to treat urinary tract infection. The increasing incidence
of resistance to earlier generation fluoroquinolones pointed
to the need of newer generation antibiotics [13, 14]. The
second-generation fluoroquinolones include ciprofloxacin
and ofloxacin; third-generation fluoroquinolones include
levofloxacin, fourth-generation fluoroquinolones include
moxifloxacin and gatifloxacin. The advances in molecular
structures of fourth-generation fluoroquinolones, that is,
moxifloxacin and gatifloxacin, resulted in inhibition of
both DNA gyrase and topoisomerase IV in Gram-positive
bacteria [15]. These changes increase the antibiotic potency
against Gram-positive organisms while maintaining their
broad spectrum activities against Gram-negative bacteria
[12]. These structural modifications also reduce the risk of
development of resistant organisms since two concomitant
mutations are necessary for the development of resistance
[16–18]. Furthermore, the structure of moxifloxacin is
resistant to bacterial cells’ efflux mechanism, thus enhancing
its potency to kill bacteria [11]. Ophthalmic application
of fluoroquinolones began in the 1990s when the second
generation fluoroquinolones like ciprofloxacin and ofloxacin
were available in topical form. They were used for the
treatment of infectious keratitis and conjunctivitis [19, 20].
In this paper, we reviewed the literature and looked into
the clinical use of fourth-generation fluoroquinolones in the
treatment of infectious keratitis.
4.1.1. In Vitro Potency of Fluoroquinolones. The potency
of antibiotics against bacteria is reflected by the mini-
mum inhibitory concentration (MIC) obtained for different
organisms during microbiological analysis. A drug with
a low MIC for a particular organism means that it has
a potent antibiotic effect on this particular organism.
Kowalski et al. determined the MIC90s of 177 bacterial
keratitis isolates to ciprofloxacin, ofloxacin, levofloxacin,
gatifloxacin, and moxifloxacin [21]. They found that the
MIC90s for Gram-positive bacteria were significantly lower
for fourth-generation fluoroquinolones than second- or
third-generations, especially for fluoroquinolone-resistant
Staphylococcus aureus (3.0 ug/mL in moxifloxacin and gat-
ifloxacin versus 64.0 ug/mL in levofloxacin, ciprofloxacin,
and ofloxacin). However, ciprofloxacin (2nd generation)
is still better than the third-and fourth-generation flu-
oroquinolones against Gram-negative organisms includ-
ing Pseudomonas aeruginosa (ciprofloxacin 0.125 ug/mL,
ofloxacin 1.5 ug/mL, levofloxacin 0.5 ug/mL, moxifloxacin
0.75 ug/mL, gatifloxacin 0.38 ug/mL). Among the two
fourth-generation fluoroquinolones, moxifloxacin demon-
strated statistically lower MIC90s for most Gram-positive
bacteria; gatifloxacin on the other hand was noted to have
lower MIC90s for most Gram-negative bacteria [21]. Sueke
et al. collected 772 bacterial isolates from cases of bacterial
keratitis in multiple centers in the United Kingdom and
tested against standard and new antibiotics [22]. Among
the fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin,
and moxifloxacin), moxifloxacin demonstrated the lowest
MICs for both Gram-positive and Gram-negative bacteria
[22]. Chawla et al. identified 292 bacterial isolates from con-
secutive cases of suspected bacterial keratitis and reviewed
their microbiological response to cefazolin, tobramycin,
gatifloxacin, and moxifloxacin [23]. Susceptibilities to mox-
ifloxacin and gatifloxacin were similar: 92.8% and 95.5%
of all the bacterial isolates were susceptible to moxifloxacin
and gatifloxacin, respectively. Only 83.6% and 90.1% of
the isolates were susceptible to cefazolin and tobramycin,
respectively [23]. A few other studies have tried to look
into the in vitro susceptibilities of bacterial isolates obtained
from ocular infections such as blepharitis, conjunctivitis,
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keratitis, and endophthalmitis to the commonly prescribed
antibiotics. Similar results regarding fluoroquinolones were
obtained in these studies in which the fourth-generation
fluoroquinolones were generally superior to other genera-
tions of fluoroquinolones in their actions on Gram-positive
bacteria [24–27]. Though consistent results were obtained
for Gram-positive organisms among these studies, in the
study by Oliveira et al., ciprofloxacin had lower MICs
than the two fourth-generation fluoroquinolones for Gram-
negative bacteria, especially for Pseudomonas species [27].
The results of in vitro studies may not be directly translated
to clinical effectiveness because there are no susceptibility
breakpoints for topically applied antibiotics to the eye.
4.1.2. Clinical Trials on Fluoroquinolones. Three clinical
trials were found in the literature investigating on the
clinical efficacy of the fourth-generation fluoroquinolones in
treating infectious keratitis. The largest study was conducted
by Constantinou et al. [28]. They recruited 229 patients with
bacterial keratitis and randomized to three treatment groups,
the moxifloxacin (1.0%) group, the ofloxacin (0.3%) group,
and the combined fortified tobramycin (1.33%)/cefazolin
(5.0%) group. All the patients were given hourly instillation
of the topical antibiotics in the first 48 hours then tapered
off according to the protocol until after the 7th day when
frequency of instillation will be adjusted according to
clinical response. Of the bacterial isolates obtained, none of
them were resistant to moxifloxacin, 2.5% were resistant to
ofloxacin, 2.8% to ciprofloxacin, 14.8% to cefazolin, 1.6% to
tobramycin, and 17.5% to chloramphenicol. The cure rate,
the mean time to cure, the clinical sign score, and the rate of
serious complications were not significantly different among
the three groups. Two patients reported stinging and one
developed ulceration of the inferior bulbar conjunctiva after
applying antibiotics eyedrops, all of them were from the for-
tified treatment group. None of these minor complications
were noted in the fluoroquinolones monotherapy groups.
Another study conducted by Parmar et al. compared the
effect of topical gatifloxacin 0.3%, a fourth-generation flu-
oroquinolone, with ciprofloxacin 0.3%, a second-generation
fluoroquinolone, for the treatment of patient with bacterial
keratitis and ulcer size of at least 2mm [29]. This study
recruited a total of 104 patients randomized to the two
treatment group, with in-patient hourly instillation of topical
antibiotics until the ulcer began to heal with dosing fre-
quencies adjusted accordingly. Culture results revealed that
significantly larger proportion of both Gram-positive and
Gram-negative bacteria were susceptible to gatifloxacin than
ciprofloxacin. 96.2% of Gram-positive cocci were susceptible
to gatifloxacin versus 60.4% to ciprofloxacin; all Gram-
positive bacilli were susceptible to gatifloxacin but only 75%
were susceptible to ciprofloxacin; 92.9% of Gram-negative
bacilli were susceptible to gatifloxacin compared to 85.7% to
ciprofloxacin. Even for Pseudomonas aeruginosa, 87.5% were
susceptible to gatifloxacin while only 75% were susceptible
to ciprofloxacin. Clinically, 95.1% of patients in gatifloxacin
group enjoyed good response and complete healing of ulcer,
which was significantly higher than the ciprofloxacin group
in which only 80.9% of patients had complete healing. The
mean time taken for the ulcer to heal was similar in the two
groups. The latest clinical study of these kinds was conducted
by Shah et al. in 2010 [30]. A total of 61 patients were
randomized to three groups comparing the clinical effects
of moxifloxacin 0.5%, gatifloxacin 0.5%, and combined
fortified tobramycin 1.3%/cefazolin 5% on bacterial keratitis.
All the patients suffered clinically from bacterial keratitis
with ulcer size between 2mm and 8mm. In this study, 46%
of the subjects had eye injury before the episode. Topical
antibiotics were instilled hourly for the first 48–72 hours
and then tapered off according to the study protocol. Of the
bacterial isolates tested, 5.2% were resistant to tobramycin
and 10.4% were resistant to cefazolin. All isolates were
susceptible to the two 4th generation fluoroquinolones under
study. The cure rates of the fortified antibiotics group was
90% and of the gatifloxacin and moxifloxacin group 95%.
However, the difference was not statistically significant. The
mean duration to heal, the final visual acuity, and the size of
the corneal opacities at the end of the study were also found
to be statistically insignificant. Two patients complained of
mild ocular discomfort after applying gatifloxacin. No other
adverse effect was reported.
4.2. Collagen Cross-Linking (CXL). Approximately 90% of
corneal thickness is composed of stroma. Corneal stroma is
made up of regularly arranged collagen fibrils with presence
of keratocytes. Bacteria and fungi produce enzymes which
have ability to digest human collagen and cause corneal
melting.
Collagen cross-linking (CXL) is a technique that uses
riboflavin and Ultraviolet-A irradiation to cause a strength-
ening effect in corneal tissue which enhances its rigidity [31–
33]. The interactive effect of riboflavin with UV-A irradiation
strengthens formation of chemical bonds between collagen
fibrils in the corneal stroma and helps in increasing resistance
against enzymatic digestion [34]. Riboflavin or vitamin
B2 is a naturally occurring substance. It is an important
micronutrient which plays a key role in maintaining health
in human beings. It was demonstrated by Japanese scientists
that when riboflavin was exposed to visible or UV light,
it could be used to inactivate the RNA containing tobacco
mosaic virus [35]. Since that discovery, this phenomenon has
been used in several subspecialties of medicine to inactivate
viruses, bacteria, and parasites [36–39]. The photoactiva-
tion of riboflavin causes damage to RNA and DNA of
microorganisms by oxidation processes and causes lesions in
the chromosomal strands [13]. In addition, the ultraviolet
irradiation itself has sporicidal and virucidal effects [40, 41].
The procedures of collagen cross-linking used in the
treatment of infectious keratitis are almost identical to the
standard protocol of treatment of keratoconus, with the
exception that after application of anaesthetic eyedrops, only
loose epithelium and the epithelium around the infectious
site were removed in infectious keratitis [42–44]. The
purpose of removing the corneal epithelium is to achieve
adequate penetration of riboflavin eye drops. Riboflavin
(riboflavin/dextran solution 0.5–0.1%) is instilled over the
surface of cornea for a period of 20–30 minutes at an interval
of 2-3 minutes. This is followed by illumination of the cornea
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using a UV-X lamp, UV-A 365 nm, with an irradiance of
3.0mW/cm2 and total dose of 5.4 J/cm2.
4.2.1. In Vitro Studies of CXL. Spoerl et al. showed that cross-
linked corneas had increased resistance against enzymatic
digestion by proteinases and collagenase [45]. Martins
et al. conducted an in vitro study to demonstrate the
antimicrobial properties of riboflavin/UVA (365 nm) against
common pathogens. They found this treatment to be effec-
tive against certain bacteria such as Staphylococcus aureus
(SA), Staphylococcus epidermidis (SE), methicillin-resistant S.
aureus (MRSA), Pseudomonas aeruginosa, and drug-resistant
Streptococcus pneumoniae but ineffective against Candida
albicans [46]. In a study by Kashiwabuchi et al., the authors
did not find treatment with UVA + riboflavin to be effective
against trophozoites of Acanthamoeba in vitro or in vivo
[47]. Despite being ineffective in the in vitro test, in a case
report by Gardun˜oVieyra et al. and, case series by Khan et al.
YA, UVA + riboflavin was shown to be effective in the
treatment of Acanthamoeba keratitis. Their patients showed
rapid reduction in ocular symptoms and ulcer size [48, 49].
4.2.2. Clinical Studies. Corneal CXL was initially used in
conditions of corneal ectasia, for example, keratoconus.
Collagen CXL increases the biomechanical strength of cornea
and helps in halting the progression of keratoconus [43, 50].
Mu¨ller et al. showed that CXL was able to improve healing
in patients with corneal melting secondary to contact lens-
related infectious keratitis [51]. Iseli et al. in their case series
of 5 patients with antibiotics treatment-resistant infectious
keratitis demonstrated the efficacy of UVA/riboflavin treat-
ment in halting the progression of corneal melting [44].
In a study by Makdoumi et al. which consisted of 7 eyes,
corneal melting was arrested and complete epithelialization
achieved in all cases after collagen cross-linking treatment
with riboflavin [42]. For the two patients presented with
hypopyon, the hypopyon regressed two days after CXL [42].
In the most recent study by Makdoumi et al., CXL has been
successfully used as the primary treatment in the subjects
with infectious keratitis [52]. Only 2 out of the 16 patients
in the study required antibiotics; one required amniotic
membrane transplantation. Ferrari et al. also reported a
case of Escherichia coli keratitis with no improvement with
topical and systemic antibiotics but started to heal after CXL
was used [53].
5. Discussion
The in vitro studies of theMIC of different antibiotics against
keratitis isolates have provided an idea of the potencies
of the fourth-generation fluoroquinolones moxifloxacin,
gatifloxacin, and tobramycin-cefazolin against pathogens
for infectious keratitis [23]. However, we cannot compare
their relative potencies because they belong to different
classes of antibiotics (fluoroquinolones, aminoglycosides,
cephalosporins) which possess different mechanisms of
action. Potency comparisons can only be made within the
same class of antibiotics. The fourth-generation fluoro-
quinolones are found to be either similar to or better than
earlier generations fluoroquinolones (e.g., ciprofloxacin,
ofloxacin, levofloxacin) in killing causative bacteria in infec-
tious corneal ulcer [21, 22, 24–47]. Generally, moxifloxacin
and gatifloxacin have higher potencies against Gram-positive
organisms while maintaining its broad-spectrum activities
against Gram-negative organisms. However, ciprofloxacin
is still better than the third- and fourth-generation flu-
oroquinolones against Gram-negative bacteria including
Pseudomonas aeruginosa [21]. As discussed, in vitro potency
may not translate directly to clinical efficacy because the
latter is also affected by the tissue penetration and the final
tissue concentration of the antibiotics. However, since topical
antibiotic eye drops in ocular tissues can usually achieve ten-
to hundred-folds higher concentrations than the usual MIC
for organisms [54, 55], even if a bacterial species is found
to be resistant to a particular antibiotic in vitro, clinically it
may still respond to that antibiotic. Also, moxifloxacin has an
advantage over other fluoroquinolones such as gatifloxacin
and levofloxacin in that it is able to achieve higher con-
junctival, corneal, and aqueous concentrations [56–60]. MIC
was also noted to be correlated to the corneal scar size after
healing of infectious keratitis. For every two-fold increase
in MIC, there will be a 0.33mm increase in the diameter
of the scar, though it is not found to be correlated with
the best corrected visual acuity [61]. Therefore, the lower
MICs of the fourth-generation fluoroquinolones shown in
the in vitro studies imply potentially better healing of the
corneal ulcer [21–27]. The results of the three clinical trials
correlate well with the results of the in vitro studies in
that fourth-generation fluoroquinolones were comparable
to fortified antibiotics and were better than the second-
generation fluoroquinolones in the treatment of infectious
keratitis [28–30]. The antibiotic resistance rates of the
bacterial isolates were consistently lower in moxifloxacin and
gatifloxacin than almost all other antibiotics. However, it is
important to note that in the study by Constantinou et al.
[28], the percentage of Gram-positive bacteria constituted
76.2% of all the bacterial isolates and Gram-negative bacteria
constituted 23.8%. In contrast, the Hong Kong and the
United Kingdom studies reported a different spectrum of
pathogens in bacterial keratitis, with 46.8% Gram-positive
and 53.2% Gram-negative in Hong Kong, [60] and 38.9%
Gram-positive and 61.1% Gram-negative in the United
Kingdom [62]. Since fourth-generation fluoroquinolones
are known to have higher potency against Gram-positive
bacteria [12] and lower potency than ciprofloxacin in the
inhibition of Pseudomonas aeruginosa [21, 27], the com-
parable efficacies of moxifloxacin, ofloxacin, and combined
fortified tobramycin/cefazolin may not be reproducible
in countries like Hong Kong and the United Kingdom,
especially when Pseudomonas aeruginosa only constituted
7% of all the isolates in Constantinou’s study but 36.4%
and 49.1% in Hong Kong and the United Kingdom. The
cure rate by moxifloxacin could possibly be lower than that
reported by Constantinou et al. This argument can also apply
to the studies conducted by Parmar et al. (81.3% Gram-
positive and 18.7%Gram-negative; 10.7%were Pseudomonas
aeruginosa) [29] and Shah et al. (culture positive cases:
85.5% Gram-positive and 14.5% Gram-negative; 11.3%
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were Pseudomonas aeruginosa) [30]. Moreover, though the
treatment failure rates were not significantly different, we
can see that the actual percentage of treatment failure was
lower in the fortified tobramycin/cefazolin group (0.0%)
than the moxifloxacin group (10.6%) and the ofloxacin
group (6.6%) [28]. Again, though not statistically significant,
the mean durations to cure were shorter in the fortified
tobramycin/cefazolin group (38.2 days) and moxifloxacin
group (36.4 days) when compared with the ofloxacin group
(46.2 days) [28]. Parmar et al. also reported that despite
statistically insignificant, only 50% (1 out of 2) of the
patients in the gatifloxacin group with Pseudomonas keratitis
healed compared to 100% (5 out of 5) in the ciprofloxacin
group [29]. This suggests that gatifloxacin may be less
effective than ciprofloxacin against Pseudomonas aeruginosa.
By sample size calculation based on an estimated difference
of 15% among groups, >85% of overall response rate and
85% probability of detecting a difference, clinical studies
need 77 subjects for each treatment group (i.e., 154 for
studies involving two intervention groups and 231 for studies
involving three intervention groups) in order to achieve
sufficient power to identify the clinical differences concerned.
Since the number of patients was too small in the study
conducted by Shah et al. (around 20 patients per group) [30]
and Parmar et al. (around 50 patients per group) [29], their
results may not be able to reach a statistically significant level
despite that a genuine difference exists. Thus, the data of
these studies should be interpreted carefully and may only be
seen as a supplement to other larger studies. The minimally
invasive technique of CXL initially used in the management
of ectatic conditions of cornea such as keratoconus, pellucid
marginal degeneration, and iatrogenic keratectasia following
laser in situ keratomileusis (LASIK) has been effectively used
for treatment of infectious keratitis with or without the
risk of corneal melting. Recent study has demonstrated the
efficacy of this treatment modality in the primary treatment
of infectious keratitis [52].
6. Conclusion
Topical fourth-generation fluoroquinolones, namely, mox-
ifloxacin and gatifloxacin, are good alternatives to com-
bination of fortified antibiotics in the management of
infectious keratitis. They may be used as empirical therapies
after corneal scraping has been performed. Low antibiotics
resistances to these two fluoroquinolones are expected in
view of their structural modifications and dual inhibition
mechanisms. However, since moxifloxacin and gatifloxacin
may not be as potent as ciprofloxacin or tobramycin against
Gram-negative organisms such as Pseudomonas aeruginosa,
further studies are warranted to compare the response of
Pseudomonas infections to these antibiotics before we can
conclude that the new fluoroquinolones are as potent as the
standard combination of fortified antibiotics in the manage-
ment of infectious keratitis. To date, only a few papers in the
literature have reported the effect of photodynamic therapy
(collagen CXL) in the management of infectious keratitis.
The results of these trials are promising and imply that this
new treatment modality may be useful in the treatment
of resistant infectious corneal ulcer or as an adjunct for
standard antibiotic treatment. However, since all of the pub-
lished studies regarding CXL as the treatment of infectious
keratitis were either based on animals or small numbers of
patients, larger scale randomized, controlled trials should
be conducted to evaluate the additional beneficial effects of
CXL in infectious keratitis on top of conventional topical
antibiotics. Furthermore, more evidence is required before
it will be advisable to use CXL as the first line treatment for
infectious corneal ulcers.
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